TipRanks
Immunocore Holdings (IMCR)
NASDAQ:IMCR
US Market
IMCR
Immunocore Holdings
RESEARCH TOOLSreports
Want to see IMCR full AI Analyst Report?

Immunocore Holdings (IMCR) Stock Forecast & Price Target

257 Followers
See the Price Targets and Ratings of:

IMCR Analyst Ratings

Moderate Buy
6Ratings
Moderate Buy
4 Buy
2 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Immunocore
Holdings
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IMCR Stock 12 Month Forecast

Average Price Target

$62.83
▲(70.98% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Immunocore Holdings in the last 3 months. The average price target is $62.83 with a high forecast of $100.00 and a low forecast of $35.00. The average price target represents a 70.98% change from the last price of $36.75.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"27":"$27","64":"$64","101":"$101","45.5":"$45.5","82.5":"$82.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":62.833333333333336,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$62.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[27,45.5,64,82.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.86,41.716923076923074,46.573846153846155,51.43076923076923,56.28769230769231,61.144615384615385,66.00153846153846,70.85846153846154,75.71538461538461,80.57230769230769,85.42923076923077,90.28615384615384,95.14307692307692,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.86,38.857948717948716,40.85589743589743,42.853846153846156,44.85179487179487,46.84974358974359,48.847692307692306,50.84564102564103,52.843589743589746,54.84153846153846,56.83948717948718,58.837435897435896,60.83538461538461,{"y":62.833333333333336,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.86,36.716923076923074,36.573846153846155,36.43076923076923,36.28769230769231,36.144615384615385,36.00153846153846,35.85846153846154,35.715384615384615,35.57230769230769,35.42923076923077,35.286153846153844,35.143076923076926,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.93,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.09,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.59,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.04,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.67,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.31,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.16,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.13,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.65,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.81,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.86,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$100.00Average Price Target$62.83Lowest Price Target$35.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on IMCR
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$100
Buy
172.11%
Upside
Reiterated
09/21/26
Analysts Are Bullish on These Healthcare Stocks: Ligand Pharma (LGND), Disc Medicine (IRON)
J.P. Morgan Analyst forecast on IMCR
Jessica Fye
J.P. Morgan
J.P. Morgan
$50
Buy
36.05%
Upside
Initiated
08/21/26
Immunocore reinstated with an Overweight at JPMorganImmunocore reinstated with an Overweight at JPMorgan
Mizuho Securities Analyst forecast on IMCR
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$35
Hold
-4.76%
Downside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Immunocore Holdings (NASDAQ: IMCR)
Morgan Stanley Analyst forecast on IMCR
Sean Laaman
Morgan Stanley
Morgan Stanley
$40→$43
Hold
17.01%
Upside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Viatris (NASDAQ: VTRS), Immunocore Holdings (NASDAQ: IMCR) and Praxis Precision Medicines (NASDAQ: PRAX)
Needham Analyst forecast on IMCR
Gil Blum
Needham
Needham
$75
Buy
104.08%
Upside
Reiterated
08/06/26
Needham Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)
Goldman Sachs Analyst forecast on IMCR
Rajan Sharma
Goldman Sachs
Goldman Sachs
$73→$74
Buy
101.36%
Upside
Reiterated
08/06/26
Analysts Are Bullish on These Healthcare Stocks: Immunocore Holdings (IMCR), Natera (NTRA)
Guggenheim Analyst forecast on IMCR
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
05/06/26
Guggenheim Sticks to Their Hold Rating for Immunocore Holdings (IMCR)
TD Cowen Analyst forecast on IMCR
Tyler Van Buren
TD Cowen
TD Cowen
$60
Buy
63.27%
Upside
Reiterated
05/06/26
Oppenheimer Analyst forecast on IMCR
Jeff Jones
Oppenheimer
Oppenheimer
$86
Buy
134.01%
Upside
Reiterated
04/20/26
Analysts Are Bullish on Top Healthcare Stocks: Legend Biotech (LEGN), Tonix Pharma (TNXP)
Wells Fargo Analyst forecast on IMCR
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$60
Buy
63.27%
Upside
Reiterated
04/14/26
Analysts Are Bullish on Top Healthcare Stocks: Takeda Pharmaceutical Co (TKPHF), Immunocore Holdings (IMCR)
Jefferies Analyst forecast on IMCR
Faisal Khurshid
Jefferies
Jefferies
$33
Hold
-10.20%
Downside
Downgraded
03/15/26
Immunocore downgraded to Hold from Buy at JefferiesImmunocore downgraded to Hold from Buy at Jefferies
UBS Analyst forecast on IMCR
Michael Yee
UBS
UBS
$55
Buy
49.66%
Upside
Initiated
01/06/26
Immunocore upgraded to Buy from Sell at UBSImmunocore upgraded to Buy from Sell at UBS
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on IMCR
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$100
Buy
172.11%
Upside
Reiterated
09/21/26
Analysts Are Bullish on These Healthcare Stocks: Ligand Pharma (LGND), Disc Medicine (IRON)
J.P. Morgan Analyst forecast on IMCR
Jessica Fye
J.P. Morgan
J.P. Morgan
$50
Buy
36.05%
Upside
Initiated
08/21/26
Immunocore reinstated with an Overweight at JPMorganImmunocore reinstated with an Overweight at JPMorgan
Mizuho Securities Analyst forecast on IMCR
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$35
Hold
-4.76%
Downside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Immunocore Holdings (NASDAQ: IMCR)
Morgan Stanley Analyst forecast on IMCR
Sean Laaman
Morgan Stanley
Morgan Stanley
$40→$43
Hold
17.01%
Upside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Viatris (NASDAQ: VTRS), Immunocore Holdings (NASDAQ: IMCR) and Praxis Precision Medicines (NASDAQ: PRAX)
Needham Analyst forecast on IMCR
Gil Blum
Needham
Needham
$75
Buy
104.08%
Upside
Reiterated
08/06/26
Needham Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)
Goldman Sachs Analyst forecast on IMCR
Rajan Sharma
Goldman Sachs
Goldman Sachs
$73→$74
Buy
101.36%
Upside
Reiterated
08/06/26
Analysts Are Bullish on These Healthcare Stocks: Immunocore Holdings (IMCR), Natera (NTRA)
Guggenheim Analyst forecast on IMCR
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
05/06/26
Guggenheim Sticks to Their Hold Rating for Immunocore Holdings (IMCR)
TD Cowen Analyst forecast on IMCR
Tyler Van Buren
TD Cowen
TD Cowen
$60
Buy
63.27%
Upside
Reiterated
05/06/26
Oppenheimer Analyst forecast on IMCR
Jeff Jones
Oppenheimer
Oppenheimer
$86
Buy
134.01%
Upside
Reiterated
04/20/26
Analysts Are Bullish on Top Healthcare Stocks: Legend Biotech (LEGN), Tonix Pharma (TNXP)
Wells Fargo Analyst forecast on IMCR
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$60
Buy
63.27%
Upside
Reiterated
04/14/26
Analysts Are Bullish on Top Healthcare Stocks: Takeda Pharmaceutical Co (TKPHF), Immunocore Holdings (IMCR)
Jefferies Analyst forecast on IMCR
Faisal Khurshid
Jefferies
Jefferies
$33
Hold
-10.20%
Downside
Downgraded
03/15/26
Immunocore downgraded to Hold from Buy at JefferiesImmunocore downgraded to Hold from Buy at Jefferies
UBS Analyst forecast on IMCR
Michael Yee
UBS
UBS
$55
Buy
49.66%
Upside
Initiated
01/06/26
Immunocore upgraded to Buy from Sell at UBSImmunocore upgraded to Buy from Sell at UBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
OVIDOvid Therapeutics
WSTWest Pharmaceutical Services
ZYMEZymeworks
SLDBSolid Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immunocore Holdings

3 Months
Gil BlumNeedham
Success Rate
10/21 ratings generated profit
48%
Average Return
-2.30%
Copying Gil Blum's trades and holding each position for 3 Months would result in 47.62% of your transactions generating a profit, with an average return of -2.30% per trade.
1 Year
Jessica FyeJ.P. Morgan
Success Rate
7/14 ratings generated profit
50%
Average Return
+7.74%
Copying Jessica Fye's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +7.74% per trade.
2 Years
Jessica FyeJ.P. Morgan
Success Rate
6/14 ratings generated profit
43%
Average Return
-0.17%
Copying Jessica Fye's trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of -0.17% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMCR Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
13
14
7
5
4
Buy
0
0
0
1
1
Hold
4
3
2
2
2
Sell
0
0
1
1
1
Strong Sell
0
0
0
0
0
total
17
17
10
9
8
In the current month, IMCR has received 5 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. IMCR average Analyst price target in the past 3 months is 62.83.
Each month's total comprises the sum of three months' worth of ratings.

IMCR Financial Forecast

IMCR Earnings Forecast

Next quarter’s earnings estimate for IMCR is -$0.12 with a range of -$0.26 to $0.02. The previous quarter’s EPS was -$0.02. IMCR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IMCR has Performed in-line its overall industry.
Next quarter’s earnings estimate for IMCR is -$0.12 with a range of -$0.26 to $0.02. The previous quarter’s EPS was -$0.02. IMCR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IMCR has Performed in-line its overall industry.

IMCR Sales Forecast

Next quarter’s sales forecast for IMCR is $113.35M with a range of $108.36M to $118.40M. The previous quarter’s sales results were $116.14M. IMCR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IMCR has Performed in-line its overall industry.
Next quarter’s sales forecast for IMCR is $113.35M with a range of $108.36M to $118.40M. The previous quarter’s sales results were $116.14M. IMCR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IMCR has Performed in-line its overall industry.

IMCR Stock Forecast FAQ

What is IMCR’s average 12-month price target, according to analysts?
Based on analyst ratings, Immunocore Holdings’s 12-month average price target is 62.83.
    What is IMCR’s upside potential, based on the analysts’ average price target?
    Immunocore Holdings has 70.98% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IMCR a Buy, Sell or Hold?
          Immunocore Holdings has a consensus rating of Moderate Buy which is based on 4 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Immunocore Holdings’s price target?
            The average price target for Immunocore Holdings is 62.83. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $100.00 ,the lowest forecast is $35.00. The average price target represents 70.98% Increase from the current price of $36.75.
              What do analysts say about Immunocore Holdings?
              Immunocore Holdings’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of IMCR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.